Landos Biopharma, Inc.
LABPNASDAQHealthcare
$22.93
+$0.13(+0.57%)
Market Cap$71675511
P/E Ratio—
52W High$22.94
52W Low$3.145
Landos Biopharma, Inc. (LABP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LABP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 9, 2024EPS Actual
-$1.43
Est. -$1.00 · -43.0%
Revenue
—
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 9, 2024
After Market Close
▼ Miss EPS
LABP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 9, 2024 | -$1.00 | -$1.43 | -43.0% | — | — | — |
| ▼ Q1 FY2024 | Mar 21, 2024 | -$0.91 | -$0.99 | -8.8% | — | — | — |
| ▼ Q4 FY2023 | Nov 9, 2023 | -$0.79 | -$0.94 | -19.0% | — | — | — |
| ▲ Q3 FY2023 | Aug 9, 2023 | -$1.10 | -$0.63 | +42.7% | — | — | — |
| ▲ Q2 FY2023 | May 12, 2023 | -$1.00 | -$0.90 | +10.0% | — | — | — |
| ▲ Q1 FY2023 | Mar 23, 2023 | -$1.50 | -$1.30 | +13.3% | — | — | — |
| ▲ Q4 FY2022 | Nov 10, 2022 | -$2.90 | -$2.00 | +31.0% | — | — | — |
| ▲ Q3 FY2022 | Aug 11, 2022 | -$3.70 | -$2.80 | +24.3% | — | — | — |
Q2 FY2024
May 9, 2024Miss
EPS Actual
-$1.43
EPS Est.
-$1.00
EPS Surpr.
-43.0%
Revenue
—
Q1 FY2024
Mar 21, 2024Miss
EPS Actual
-$0.99
EPS Est.
-$0.91
EPS Surpr.
-8.8%
Revenue
—
Q4 FY2023
Nov 9, 2023Miss
EPS Actual
-$0.94
EPS Est.
-$0.79
EPS Surpr.
-19.0%
Revenue
—
Q3 FY2023
Aug 9, 2023Beat
EPS Actual
-$0.63
EPS Est.
-$1.10
EPS Surpr.
+42.7%
Revenue
—
Q2 FY2023
May 12, 2023Beat
EPS Actual
-$0.90
EPS Est.
-$1.00
EPS Surpr.
+10.0%
Revenue
—
Q1 FY2023
Mar 23, 2023Beat
EPS Actual
-$1.30
EPS Est.
-$1.50
EPS Surpr.
+13.3%
Revenue
—
Q4 FY2022
Nov 10, 2022Beat
EPS Actual
-$2.00
EPS Est.
-$2.90
EPS Surpr.
+31.0%
Revenue
—
Q3 FY2022
Aug 11, 2022Beat
EPS Actual
-$2.80
EPS Est.
-$3.70
EPS Surpr.
+24.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q3 FY2025 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q2 FY2025 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q1 FY2025 | $-0.67 | $-0.67 | $-0.67 | 1 |
| Q4 FY2024 | $-0.53 | $-0.53 | $-0.53 | 1 |
| Q3 FY2024 | $-0.67 | $-0.48 | $-0.29 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 9, 2024 | -43.0% | $22.21 | $22.36 | +0.68% |
| ▼ Q1 FY2024 | Mar 21, 2024 | -8.8% | $6.99 | $7.67 | +9.73% |
| ▼ Q4 FY2023 | Nov 9, 2023 | -19.0% | $4.14 | $3.83 | -7.49% |
| ▲ Q3 FY2023 | Aug 9, 2023 | +42.7% | $4.00 | $4.10 | +2.50% |
| ▲ Q2 FY2023 | May 12, 2023 | +10.0% | $2.95 | $2.98 | +1.02% |
| ▲ Q1 FY2023 | Mar 23, 2023 | +13.3% | $2.96 | $2.60 | -12.16% |
| ▲ Q4 FY2022 | Nov 10, 2022 | +31.0% | $2.30 | $2.70 | +17.39% |
| ▲ Q3 FY2022 | Aug 11, 2022 | +24.3% | $12.30 | $10.80 | -12.20% |
Q2 FY2024+0.68%
Report Date
May 9, 2024
EPS Beat/Miss
-43.0%
Price Before
$22.21
Price After
$22.36
Q1 FY2024+9.73%
Report Date
Mar 21, 2024
EPS Beat/Miss
-8.8%
Price Before
$6.99
Price After
$7.67
Q4 FY2023-7.49%
Report Date
Nov 9, 2023
EPS Beat/Miss
-19.0%
Price Before
$4.14
Price After
$3.83
Q3 FY2023+2.50%
Report Date
Aug 9, 2023
EPS Beat/Miss
+42.7%
Price Before
$4.00
Price After
$4.10
Q2 FY2023+1.02%
Report Date
May 12, 2023
EPS Beat/Miss
+10.0%
Price Before
$2.95
Price After
$2.98
Q1 FY2023-12.16%
Report Date
Mar 23, 2023
EPS Beat/Miss
+13.3%
Price Before
$2.96
Price After
$2.60
Q4 FY2022+17.39%
Report Date
Nov 10, 2022
EPS Beat/Miss
+31.0%
Price Before
$2.30
Price After
$2.70
Q3 FY2022-12.20%
Report Date
Aug 11, 2022
EPS Beat/Miss
+24.3%
Price Before
$12.30
Price After
$10.80
Avg Beat Reaction-0.69%
Avg Miss Reaction+0.97%
Beat Rate5 / 8 quarters
Largest Move+17.39% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LABP ends December
Landos Biopharma, Inc. (LABP) most recently reported earnings on May 9, 2024 for Q2 FY2024, posting EPS of $-1.43 — missing the analyst consensus of $-1.00 by -43.0%. The next LABP earnings date is expected around September 1, 2026.
Each quarter, investors track LABP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LABP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LABP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LABP earnings · 5 questionsLandos Biopharma, Inc.'s next earnings report is expected around September 1, 2026. LABP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LABP historically reports after market close (AMC).
LABP earnings datewhen is LABP earningsLABP next earnings datewhen does LABP report earningsLABP earnings calendar
▸ Source: FMP · Landos Biopharma, Inc. SEC filings · US GAAP · Landos Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026